Related references
Note: Only part of the references are listed.Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
Ola Landgren et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding
Youn K. Shim et al.
BLOOD (2014)
Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma
Benjamin Thiele et al.
BLOOD (2014)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients
Ravi Vij et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Minimal Residual Disease: What Are the Minimum Requirements?
Mark Roschewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N. Puig et al.
LEUKEMIA (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Improved long-term survival in multiple myeloma up to the age of 80 years
S. Y. Kristinsson et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders et al.
BLOOD (2013)
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
Joaquin Martinez-Lopez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
Prashant Kapoor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
Andy C. Rawstron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Maria-Victoria Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
Mark Korthals et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
Martin Trepel et al.
PLOS ONE (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni et al.
BLOOD (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
Aaron C. Logan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
Ingemar Turesson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma
Sham Mailankody et al.
LEUKEMIA & LYMPHOMA (2010)
Treatment of newly diagnosed multiple myeloma: advances in current therapy
Shaji Kumar
MEDICAL ONCOLOGY (2010)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
Andy C. Rawstron et al.
HAEMATOLOGICA (2008)
Multiple myeloma cancer stem cells
Carol Ann Huff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
AC Rawstron et al.
BLOOD (2002)
Share Paper
